Junttila Teemu T, Tanner Minna, Isola Jorma
Roche-Genentech Inc. South San Francisco, California, USA.
Duodecim. 2011;127(4):343-9.
First generation antibody drugs recognize the cancer cell, slow down the signaling of cell growth and activate the defense response. Second generation antibody drugs contain conjugated cytotoxic agents that are activated upon entry into the cancer cell. Trastuzumab has become established among the first generation antibody drugs utilized in breast cancer therapy, and its derivative trastuzumab-DM1 is the first antibody-drug conjugate currently in clinical trials for breast cancer. Trastuzumab acts as an antibody and transports into the cancer cell the cytotoxic agent DM1, which becomes activated there. Targeted cytotoxic drugs are under development for the treatment of many different types of cancer.
第一代抗体药物识别癌细胞，减缓细胞生长信号并激活防御反应。第二代抗体药物含有偶联的细胞毒性药物，这些药物在进入癌细胞后被激活。曲妥珠单抗已成为乳腺癌治疗中使用的第一代抗体药物之一，其衍生物曲妥珠单抗-DM1是目前正在进行乳腺癌临床试验的首个抗体药物偶联物。曲妥珠单抗作为一种抗体，将细胞毒性药物DM1转运到癌细胞中，DM1在癌细胞中被激活。靶向细胞毒性药物正在研发中，用于治疗多种不同类型的癌症。
